uniQure N.V. (QURE)

uniQure's stock has experienced volatility. In November 2025, the share price was $27.96, a 362.15% increase year-over-year, but it declined by -55.18% in the last month. The stock price fell over 50% in early November 2025 due to FDA feedback on AMT-130. In September 2025, uniQure raised approximately $323.7 million through an upsized public offering. In July 2024, the stock surged 76.5% following positive data from AMT-130 studies.

There is no specific data indicating demand seasonality for uniQure N.V.'s products and services. Demand is likely driven by disease incidence, diagnosis, and regulatory approvals rather than seasonal factors.

uniQure N.V. is a biotechnology company focused on gene therapies for rare and severe diseases, utilizing an AAV-based technology platform. Its key products include HEMGENIX for hemophilia B, AMT-130 for Huntington's disease, AMT-260 for refractory mesial temporal lobe epilepsy, AMT-191 for Fabry disease, and AMT-162 for amyotrophic lateral sclerosis.

uniQure N.V. is headquartered in Amsterdam, with operations in the United States, the Netherlands, and Switzerland. It has a manufacturing facility in Lexington, Massachusetts.

uniQure's brand reputation has been influenced by positive clinical data and regulatory challenges. Positive top-line data for AMT-130 and advancements in other pipeline programs have contributed positively. However, FDA regulatory hurdles for AMT-130, the pause in the AMT-162 program, and increased expenses have presented challenges.

Institutional owners hold 54% of uniQure's shares, with the top 14 shareholders holding 51%. Major institutional owners include Fmr Llc, Avoro Capital Advisors LLC, and RTW Investments, LP. The general public holds a 17% stake, and insiders hold approximately 2.21%.